Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
11 hedge funds and large institutions have $84K invested in Aoxing Pharmaceutical Company Inc. in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
8% less funds holding
Funds holding: 12 → 11 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
52% less capital invested
Capital invested by funds: $176K → $84K (-$92K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$22.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.73K |
| 3 |
Renaissance Technologies
New York
|
+$8.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36.6K |
| 2 |
Bank of New York Mellon
New York
|
-$28K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$3.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $20K | +$22.2K | +53,621 | +527% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $18K | -$36.6K | -88,445 | -61% |
|
3
Barclays
London,
United Kingdom
| $8K | – | – | – |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $8K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $8K | +$8.73K | +21,081 | +471% |
|
|
VKH
6
Virtu KCG Holdings
New York
| $7K | -$3.72K | -8,984 | -28% |
|
|
7
Renaissance Technologies
New York
| $7K | +$8.54K | +20,620 | New |
|
|
EWM
8
Evercore Wealth Management
New York
| $4K | – | – | – |
|
9
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
|
FWM
10
Focused Wealth Management
Newburgh,
New York
| $2K | – | – | – |
|
|
11
Bank of New York Mellon
New York
| – | -$28K | -50,592 | Closed |
|
AXN Hedge Fund Activity: Q4 2016 in Review
11 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q4 2016, worth a combined $84K — down 52% from $176K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AXN and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, adding an estimated $22.2K. The largest seller was Susquehanna International Group, cutting an estimated $36.6K.
- 11 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q4 2016, down from 12 in Q3 2016.
- Funds reported $84K of Aoxing Pharmaceutical Company Inc. stock for Q4 2016, down 52% quarter-over-quarter.
- 1 fund opened new Aoxing Pharmaceutical Company Inc. positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q4 2016 was Citadel Advisors, an estimated $22.2K added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q4 2016 was Susquehanna International Group, an estimated $36.6K sold.
Based on aggregated 13F filings for Q4 2016.